Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Methods & Clinical Development
- Vol. 17, 871-893
- https://doi.org/10.1016/j.omtm.2020.03.028
Abstract
No abstract availableKeywords
Funding Information
- NIH (U01NS061811, P01CA163205, R01NS110942, P01CA236749)
- Alliance for Cancer Gene Therapy
This publication has 86 references indexed in Scilit:
- Effect of γ34.5 Deletions on Oncolytic Herpes Simplex Virus Activity in Brain TumorsJournal of Virology, 2012
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic AdenovirusMolecular Therapy, 2011
- ICP34.5 Protein of Herpes Simplex Virus Facilitates the Initiation of Protein Translation by Bridging Eukaryotic Initiation Factor 2α (eIF2α) and Protein Phosphatase 1Online Journal of Public Health Informatics, 2011
- Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeuticsGene Therapy, 2010
- Control of TANK-binding Kinase 1-mediated Signaling by the γ134.5 Protein of Herpes Simplex Virus 1Online Journal of Public Health Informatics, 2009
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With CyclophosphamideMolecular Therapy, 2008
- Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without CyclophosphamideClinical Pharmacology & Therapeutics, 2007
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences of the United States of America, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005